Sen-Jam Pharmaceutical just dropped a patent filing that might make Big Pharma sweat. The Huntington-based biopharma expanded its addiction therapeutic platform with a U.S. provisional patent titled “Compositions and Methods for Stimulant Withdrawal.” Translation, they’re taking aim at the methamphetamine epidemic, a $217B problem space with zero FDA-approved treatments.
This move isn’t luck. It’s the product of two sharp minds, Co-Founders Jim Iversen and Jacqueline M. Iversen, RPh, MS. Jim Iversen brings logistics and entrepreneurial muscle that’s already turned five exits into $730M in value. Jacqueline Iversen brings the science, trained at Memorial Sloan Kettering, University at Buffalo, and St. John’s University. She built Sen-Jam’s PAIR (Pleiotropic Anti-Inflammatory Regulators) platform on one radical insight: inflammation isn’t the symptom, it’s the source.
That insight rewired how Sen-Jam sees disease. Instead of chasing pain downstream, they go upstream, pairing FDA-approved molecules into new, synergistic therapies that hit multiple inflammatory pathways at once. Think of it as precision remixing, same notes, new harmony. It’s the kind of play that lets a lean team punch far above its weight, cutting time, cost, and regulatory risk while generating new IP that stretches into the 2040s.
And investors noticed. 5 Horizons Capital, led by Managing Director Aaron Ray, anchored the company’s Phase 2 trial of SJP-001, a hangover prevention and metabolic health therapeutic in Canada and Australia. Add strategic partners like KVK-Tech, Desire Ventures, and nearly a thousand crowdfunders through WeFunder and StartEngine, and you’ve got a company democratizing biotech finance without diluting scientific integrity.
Sen-Jam isn’t just stacking patents; they’re building a full pipeline. SJP-001 targets alcohol indulgence. SJP-002C takes aim at upper respiratory infections, including COVID-19. SJP-005 tackles opioid withdrawal with NIDA. And now, this stimulant withdrawal program, built on the same PAIR platform, is taking on methamphetamine dependence where the market is massive and the options are nonexistent.
Behind the lab coats, what’s happening here is bigger than biochemistry. It’s a story about access, about who gets to play in pharma and who benefits from the outcome. Sen-Jam is making a $217 billion market feel human again, crowdfunded, community-backed, clinically validated.
